Vaishali Verma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vaishali Verma has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Abhishek Kasana
Department of Biotechnology, School of Engineering and Applied Sciences, Bennett University, Greater Noida, India
5 shared publications Abhishek Kasana
Bennett University
3 shared publications- Abhavya Raja
Bennett University
2 shared publications - Nimisha Sinha
University of Delhi
2 shared publications - Priyadharshini Babu
Centre for Disaster Mitigation and Management (CDMM), Vellore Institute of Technology, Vellore, India
2 shared publications A. Mark Richards
Cardiovascular Research Institute, NUHS, Singapore, Singapore
1 shared publication
Latest Publications
- 22 August 2026
- Published by Springer Nature in Current Pharmacology Reports
- Vol. 12 (1) , 33
Bispecific Antibody-Drug Conjugates in Oncology: Design Principles, Clinical Progress, and Challenges
- 22 August 2026
- Published by Springer Nature in Current Pharmacology Reports
- Vol. 12 (1) , 33
Bispecific Antibody-Drug Conjugates in Oncology: Design Principles, Clinical Progress, and Challenges
- 18 November 2025
- Published by Springer Nature in Microchimica Acta
- Vol. 192 (12) , 827
Rapid and sensitive detection of OXA-23-mediated carbapenem resistance in Acinetobacter baumannii using a paper-based immunoassay with silver-based signal amplification
Increased incidence of infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) in intensive care units has necessitated the development of rapid diagnostics. Resistance is primarily caused by OXA-type carbapenemases, of which OXA-23 is the most widespread. This study describes the development of recombinant monoclonal antibodies targeting OXA-23 and their application in a paper-based assay for rapid CRAB detection. Six scFv binders were identified from an immunized phage-displayed mouse antibody library against the OXA-23 protein, of which scFv 11 and 13 exhibited high sensitivity. These clones retained their binding activity in the presence of detergent-based cell lysis buffer and demonstrated specific detection of OXA-23 with no cross-reactivity to related carbapenemases. A paper-based visual detection assay was designed using mono-biotinylated OXA scFv 11 and streptavidin-conjugated gold nanoparticles as detector molecules, with a provision for silver-based color enhancement for signal amplification. The assay enabled the detection of OXA-23-producing A. baumannii at a limit of 1 × 10⁴ CFU/ml within 30 min, from culture lysis to result interpretation. This detection limit aligns with the bacterial loads typically observed in ventilator-associated pneumonia, highlighting the suitability of the assay for clinically relevant detection. The assay showed 100% sensitivity and 100% specificity when evaluated against well-characterized clinical isolates. It offers operational ease, and clinically relevant sensitivity and specificity comparable to existing immunochromatographic platforms. The silver-based color enhancement step further improves visual identification, thereby allowing the unambiguous detection of low bacterial loads without the need for complex instrumentation. The assay is expected to facilitate early resistance detection in CRAB and improve clinical decision-making. Graphical Abstract
- 18 November 2025
- Published by Springer Nature in Microchimica Acta
- Vol. 192 (12) , 827
Rapid and sensitive detection of OXA-23-mediated carbapenem resistance in Acinetobacter baumannii using a paper-based immunoassay with silver-based signal amplification
Increased incidence of infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) in intensive care units has necessitated the development of rapid diagnostics. Resistance is primarily caused by OXA-type carbapenemases, of which OXA-23 is the most widespread. This study describes the development of recombinant monoclonal antibodies targeting OXA-23 and their application in a paper-based assay for rapid CRAB detection. Six scFv binders were identified from an immunized phage-displayed mouse antibody library against the OXA-23 protein, of which scFv 11 and 13 exhibited high sensitivity. These clones retained their binding activity in the presence of detergent-based cell lysis buffer and demonstrated specific detection of OXA-23 with no cross-reactivity to related carbapenemases. A paper-based visual detection assay was designed using mono-biotinylated OXA scFv 11 and streptavidin-conjugated gold nanoparticles as detector molecules, with a provision for silver-based color enhancement for signal amplification. The assay enabled the detection of OXA-23-producing A. baumannii at a limit of 1 × 10⁴ CFU/ml within 30 min, from culture lysis to result interpretation. This detection limit aligns with the bacterial loads typically observed in ventilator-associated pneumonia, highlighting the suitability of the assay for clinically relevant detection. The assay showed 100% sensitivity and 100% specificity when evaluated against well-characterized clinical isolates. It offers operational ease, and clinically relevant sensitivity and specificity comparable to existing immunochromatographic platforms. The silver-based color enhancement step further improves visual identification, thereby allowing the unambiguous detection of low bacterial loads without the need for complex instrumentation. The assay is expected to facilitate early resistance detection in CRAB and improve clinical decision-making. Graphical Abstract
- 11 November 2025
- Published by Springer Nature in Current Pharmacology Reports
- Vol. 11 (1) , 1-14
From Phage Surface to Bedside: Development of Therapeutic Monoclonal Antibodies using Phage Display
- 11 November 2025
- Published by Springer Nature in Current Pharmacology Reports
- Vol. 11 (1) , 1-14
From Phage Surface to Bedside: Development of Therapeutic Monoclonal Antibodies using Phage Display
- 30 July 2025
- Published by Springer Nature
- p. 245-264
Enzyme-Based Textile Finishing: Leveraging Biological Catalysts in Textile Industry
- 30 July 2025
- Published by Springer Nature
- p. 245-264
Enzyme-Based Textile Finishing: Leveraging Biological Catalysts in Textile Industry
- 11 May 2025
- Published by Springer Nature
- p. 181-208
Food-Derived Bioactive Peptides as Potential Antimicrobial Agents: Challenges and Opportunities
- 11 May 2025
- Published by Springer Nature
- p. 181-208
Food-Derived Bioactive Peptides as Potential Antimicrobial Agents: Challenges and Opportunities
- Open Access
- 9 April 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2486390
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics
Viral infections remain a significant global health threat, with emerging and reemerging viruses causing epidemics and pandemics. Despite advancements in antiviral therapies, the development of effective treatments is often hindered by challenges, such as viral resistance and the emergence of new strains. In this context, the development of novel therapeutic modalities is essential to combat notorious viruses. While traditional monoclonal antibodies are widely used for the treatment of several diseases, nanobodies derived from heavy chain-only antibodies have emerged as promising "nanoscale warriors" against viral infections. Nanobodies possess unique structural properties that enhance their ability to recognize diverse epitopes. Their small size also imparts properties, such as improved bioavailability, solubility, stability, and proteolytic resistance, making them an ideal class of therapeutics for viral infections. In this review, we discuss the role of nanobodies as antivirals against various viruses. Techniques used for developing nanobodies, delivery strategies are covered, and the challenges and opportunities associated with their use as antiviral therapies are discussed. We also offer insights into the future of nanobody-based antiviral research to support the development of new strategies for managing viral infections.
- 9 April 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2486390
Open AccessNanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics
Viral infections remain a significant global health threat, with emerging and reemerging viruses causing epidemics and pandemics. Despite advancements in antiviral therapies, the development of effective treatments is often hindered by challenges, such as viral resistance and the emergence of new strains. In this context, the development of novel therapeutic modalities is essential to combat notorious viruses. While traditional monoclonal antibodies are widely used for the treatment of several diseases, nanobodies derived from heavy chain-only antibodies have emerged as promising "nanoscale warriors" against viral infections. Nanobodies possess unique structural properties that enhance their ability to recognize diverse epitopes. Their small size also imparts properties, such as improved bioavailability, solubility, stability, and proteolytic resistance, making them an ideal class of therapeutics for viral infections. In this review, we discuss the role of nanobodies as antivirals against various viruses. Techniques used for developing nanobodies, delivery strategies are covered, and the challenges and opportunities associated with their use as antiviral therapies are discussed. We also offer insights into the future of nanobody-based antiviral research to support the development of new strategies for managing viral infections.
- Open Access
- 1 January 2025
- Published by Open Science Publishers LLP in Journal of Applied Biology & Biotechnology
- Vol. 13 (2) , 20-31
Monoclonal antibodies for diagnosis of viral diseases: a comprehensive review
Viruses cause infectious diseases in humans, ranging from mild to life-threatening. Early and accurate diagnosis is essential for timely treatment and prevention of complications. Diagnostic methods typically rely on detecting viral genetic material, proteins, or the host’s immune response, depending on the infection stage. Monoclonal antibodies, known for their specificity and high affinity, are widely used for diagnosing viral infections by enabling precise and sensitive detection of viral proteins. This review explores the applications of monoclonal antibody-based methods for detecting viral infections, emphasizing their pivotal role as sensitive detection reagents. These methods are crucial for developing robust immunodiagnostic assays capable of diagnosing various viral diseases in human, animal, and plant hosts, with special emphasis on SARS-CoV-2. The review also explores various assays that employ monoclonal antibodies for diagnostic purposes and the technologies used for their production. Understanding the principles and applications of monoclonal antibodies in diagnosing viral diseases is essential for implementing effective public health interventions and preventing future pandemics.
- 1 January 2025
- Published by Open Science Publishers LLP in Journal of Applied Biology & Biotechnology
- Vol. 13 (2) , 20-31
Open AccessMonoclonal antibodies for diagnosis of viral diseases: a comprehensive review
Viruses cause infectious diseases in humans, ranging from mild to life-threatening. Early and accurate diagnosis is essential for timely treatment and prevention of complications. Diagnostic methods typically rely on detecting viral genetic material, proteins, or the host’s immune response, depending on the infection stage. Monoclonal antibodies, known for their specificity and high affinity, are widely used for diagnosing viral infections by enabling precise and sensitive detection of viral proteins. This review explores the applications of monoclonal antibody-based methods for detecting viral infections, emphasizing their pivotal role as sensitive detection reagents. These methods are crucial for developing robust immunodiagnostic assays capable of diagnosing various viral diseases in human, animal, and plant hosts, with special emphasis on SARS-CoV-2. The review also explores various assays that employ monoclonal antibodies for diagnostic purposes and the technologies used for their production. Understanding the principles and applications of monoclonal antibodies in diagnosing viral diseases is essential for implementing effective public health interventions and preventing future pandemics.
- 2 September 2024
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (9) , 3345-3365
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges
The field of cancer treatment has evolved significantly over the last decade with the emergence of next-generation therapeutic antibodies. Conventional treatments like chemotherapy pose significant challenges, including adverse side effects. Monoclonal antibodies have paved the way for more targeted and effective interventions. The evolution from chimeric to humanized and fully human antibodies has led to a reduction in immunogenicity and enhanced tolerance in vivo. The advent of next-generation antibodies, including bispecific antibodies, nanobodies, antibody-drug conjugates, glyco-engineered antibodies, and antibody fragments, represents a leap forward in cancer therapy. These innovations offer increased potency, adaptability, and reduced drug resistance. Challenges such as target validation, immunogenicity, and high production costs exist. However, technological advancements in antibody engineering techniques provide optimism for addressing these issues. The future promises a paradigm shift, where ongoing research will propel these powerful antibodies to the forefront, revolutionizing the fight against cancer and creating new preventive and curative treatments. This review provides an overview of three next-generation antibody-based molecules, namely bispecific antibodies, antibody-drug conjugates, and nanobodies that have shown promising results in cancer treatment. It discusses the evolution of antibodies from conventional forms to next-generation molecules, along with their applications in cancer treatment, production methods, and associated challenges. The review aims to offer researchers insights into the evolving landscape of next-generation antibody-based cancer therapeutics and their potential to revolutionize treatment strategies.
- 2 September 2024
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (9) , 3345-3365
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges
The field of cancer treatment has evolved significantly over the last decade with the emergence of next-generation therapeutic antibodies. Conventional treatments like chemotherapy pose significant challenges, including adverse side effects. Monoclonal antibodies have paved the way for more targeted and effective interventions. The evolution from chimeric to humanized and fully human antibodies has led to a reduction in immunogenicity and enhanced tolerance in vivo. The advent of next-generation antibodies, including bispecific antibodies, nanobodies, antibody-drug conjugates, glyco-engineered antibodies, and antibody fragments, represents a leap forward in cancer therapy. These innovations offer increased potency, adaptability, and reduced drug resistance. Challenges such as target validation, immunogenicity, and high production costs exist. However, technological advancements in antibody engineering techniques provide optimism for addressing these issues. The future promises a paradigm shift, where ongoing research will propel these powerful antibodies to the forefront, revolutionizing the fight against cancer and creating new preventive and curative treatments. This review provides an overview of three next-generation antibody-based molecules, namely bispecific antibodies, antibody-drug conjugates, and nanobodies that have shown promising results in cancer treatment. It discusses the evolution of antibodies from conventional forms to next-generation molecules, along with their applications in cancer treatment, production methods, and associated challenges. The review aims to offer researchers insights into the evolving landscape of next-generation antibody-based cancer therapeutics and their potential to revolutionize treatment strategies.
- 8 January 2024
- Published by Springer Nature in Air Quality, Atmosphere & Health
- Vol. 17 (5) , 1107-1133
Exploring the association between air pollution and spontaneous abortion through systematic review and bibliometric analysis
- 8 January 2024
- Published by Springer Nature in Air Quality, Atmosphere & Health
- Vol. 17 (5) , 1107-1133
Exploring the association between air pollution and spontaneous abortion through systematic review and bibliometric analysis
- Open Access
- 1 January 2024
- Published by Open Science Publishers LLP in Journal of Applied Biology & Biotechnology
Production of recombinant OXA-23 carbapenemase: a target for developing antibody-based diagnostics against carbapenem-resistant Acinetobacter baumannii
Carbapenems are typically the treatment of choice for drug-resistant Acinetobacter baumannii; however, the emergence of carbapenem-resistant strains has elevated this pathogen to the World Health Organization’s critical priority pathogen list. Since carbapenem resistance is frequently mediated by carbapenemases, particularly oxacillinases and metallo-beta-lactamases, antibody-based carbapenemase detection tests can be developed for rapid and affordable diagnosis of the infection. However, the development of such tests requires the availability of high-quality target proteins for generating specific antibodies, their characterization, and assay optimization. In this study, we reported a streamlined workflow to obtain a purified preparation of the tagless and functionally active recombinant OXA-23 enzyme, which is one of the major factors responsible for carbapenem resistance in Acinetobacter baumannii. The recombinant protein was expressed in the heterologous expression host Escherichia coli using auto-induction and purified using a single step of chromatography, followed by the removal of the affinity tag using TEV protease. The simple protocol reported here is expected to facilitate the production of other carbapenemases and similar proteins for the development of diagnostics and therapeutics to support the fight against antimicrobial-resistant bacteria.
- 1 January 2024
- Published by Open Science Publishers LLP in Journal of Applied Biology & Biotechnology
Open AccessProduction of recombinant OXA-23 carbapenemase: a target for developing antibody-based diagnostics against carbapenem-resistant Acinetobacter baumannii
Carbapenems are typically the treatment of choice for drug-resistant Acinetobacter baumannii; however, the emergence of carbapenem-resistant strains has elevated this pathogen to the World Health Organization’s critical priority pathogen list. Since carbapenem resistance is frequently mediated by carbapenemases, particularly oxacillinases and metallo-beta-lactamases, antibody-based carbapenemase detection tests can be developed for rapid and affordable diagnosis of the infection. However, the development of such tests requires the availability of high-quality target proteins for generating specific antibodies, their characterization, and assay optimization. In this study, we reported a streamlined workflow to obtain a purified preparation of the tagless and functionally active recombinant OXA-23 enzyme, which is one of the major factors responsible for carbapenem resistance in Acinetobacter baumannii. The recombinant protein was expressed in the heterologous expression host Escherichia coli using auto-induction and purified using a single step of chromatography, followed by the removal of the affinity tag using TEV protease. The simple protocol reported here is expected to facilitate the production of other carbapenemases and similar proteins for the development of diagnostics and therapeutics to support the fight against antimicrobial-resistant bacteria.